Keamanan Penggunaan Antiglukolan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial Fibrilasi
Atrial fibrillation can cause stroke due to blood stasis in the left atrium which triggers thrombus formation and embolization of the brain. Administration of anticoagulants is used to prevent clot formation to prevent the occurrence of stroke, but on the other hand, it is associated with the risk o...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Indonesian |
| Published: |
Universitas Gadjah Mada
2022-09-01
|
| Series: | Jurnal Manajemen dan Pelayanan Farmasi |
| Subjects: | |
| Online Access: | https://jurnal.ugm.ac.id/jmpf/article/view/74893 |
| _version_ | 1827889798591807488 |
|---|---|
| author | Juniarto Mende Fita Rahmawati Ika Puspitasari |
| author_facet | Juniarto Mende Fita Rahmawati Ika Puspitasari |
| author_sort | Juniarto Mende |
| collection | DOAJ |
| description | Atrial fibrillation can cause stroke due to blood stasis in the left atrium which triggers thrombus formation and embolization of the brain. Administration of anticoagulants is used to prevent clot formation to prevent the occurrence of stroke, but on the other hand, it is associated with the risk of bleeding side effects. This study aims to evaluate the safety of anticoagulants in ischemic stroke patients with atrial fibrillation. The study used a cross-sectional design. Retrospective data were taken from the medical records of RSUP Dr. Sardjito, Yogyakarta period January 2018 to December 2020. The research subjects were ischemic stroke patients with atrial fibrillation. Evaluation of the safety of anticoagulants includes the number of major and minor bleeding events in each type of anticoagulant and the factors that influence the occurrence of bleeding. A total of 70 patients met the study inclusion criteria. Bleeding occurred in 41 cases (58,57%). Major bleeding was 28 patients (40%) and minor bleeding was 13 patients (18,57%). The most common anticoagulant that causes bleeding is warfarin. Multivariate test of the factors that influence the occurrence of bleeding in kidney failure (OR = 5,990; 95% Cl 2,002-17,920; p = 0,001). Monitoring the side effects of anticoagulants, especially warfarin is necessary. Pharmacists can play an important role in monitoring and preventing bleeding events by taking into account risk factors, especially kidney failure. |
| first_indexed | 2024-03-12T21:00:44Z |
| format | Article |
| id | doaj.art-1ea189dee9164f41b229ca8dc6744c63 |
| institution | Directory Open Access Journal |
| issn | 2088-8139 2443-2946 |
| language | Indonesian |
| last_indexed | 2024-03-12T21:00:44Z |
| publishDate | 2022-09-01 |
| publisher | Universitas Gadjah Mada |
| record_format | Article |
| series | Jurnal Manajemen dan Pelayanan Farmasi |
| spelling | doaj.art-1ea189dee9164f41b229ca8dc6744c632023-07-31T06:53:48ZindUniversitas Gadjah MadaJurnal Manajemen dan Pelayanan Farmasi2088-81392443-29462022-09-0112317618810.22146/jmpf.7489332471Keamanan Penggunaan Antiglukolan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial FibrilasiJuniarto Mende0Fita Rahmawati1Ika Puspitasari2Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah MadaDepartemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah MadaDepartemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah MadaAtrial fibrillation can cause stroke due to blood stasis in the left atrium which triggers thrombus formation and embolization of the brain. Administration of anticoagulants is used to prevent clot formation to prevent the occurrence of stroke, but on the other hand, it is associated with the risk of bleeding side effects. This study aims to evaluate the safety of anticoagulants in ischemic stroke patients with atrial fibrillation. The study used a cross-sectional design. Retrospective data were taken from the medical records of RSUP Dr. Sardjito, Yogyakarta period January 2018 to December 2020. The research subjects were ischemic stroke patients with atrial fibrillation. Evaluation of the safety of anticoagulants includes the number of major and minor bleeding events in each type of anticoagulant and the factors that influence the occurrence of bleeding. A total of 70 patients met the study inclusion criteria. Bleeding occurred in 41 cases (58,57%). Major bleeding was 28 patients (40%) and minor bleeding was 13 patients (18,57%). The most common anticoagulant that causes bleeding is warfarin. Multivariate test of the factors that influence the occurrence of bleeding in kidney failure (OR = 5,990; 95% Cl 2,002-17,920; p = 0,001). Monitoring the side effects of anticoagulants, especially warfarin is necessary. Pharmacists can play an important role in monitoring and preventing bleeding events by taking into account risk factors, especially kidney failure.https://jurnal.ugm.ac.id/jmpf/article/view/74893antikoagulanatrial fibrilasipendarahanstroke iskemik |
| spellingShingle | Juniarto Mende Fita Rahmawati Ika Puspitasari Keamanan Penggunaan Antiglukolan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial Fibrilasi Jurnal Manajemen dan Pelayanan Farmasi antikoagulan atrial fibrilasi pendarahan stroke iskemik |
| title | Keamanan Penggunaan Antiglukolan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial Fibrilasi |
| title_full | Keamanan Penggunaan Antiglukolan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial Fibrilasi |
| title_fullStr | Keamanan Penggunaan Antiglukolan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial Fibrilasi |
| title_full_unstemmed | Keamanan Penggunaan Antiglukolan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial Fibrilasi |
| title_short | Keamanan Penggunaan Antiglukolan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial Fibrilasi |
| title_sort | keamanan penggunaan antiglukolan pada pasien rawat inap stroke iskemik dengan atrial fibrilasi |
| topic | antikoagulan atrial fibrilasi pendarahan stroke iskemik |
| url | https://jurnal.ugm.ac.id/jmpf/article/view/74893 |
| work_keys_str_mv | AT juniartomende keamananpenggunaanantiglukolanpadapasienrawatinapstrokeiskemikdenganatrialfibrilasi AT fitarahmawati keamananpenggunaanantiglukolanpadapasienrawatinapstrokeiskemikdenganatrialfibrilasi AT ikapuspitasari keamananpenggunaanantiglukolanpadapasienrawatinapstrokeiskemikdenganatrialfibrilasi |